Non-randomized phase II, open-labeled clinical study, multicenter, of docetaxel (T), cisplatin (P), 5 fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin in untreated unresectable locally-advanced Head and Neck Squamous Cell Carcinoma (HNSCC).